Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Watanabe, Yoshinori ^a,b   Nakayama, Keiko ^a   Taniuchi, Nobuhiko ^a   Horai, Yasushi ^a   Kuriyama, Chiaki ^a   Ueta, Kiichiro ^a   Arakawa, Kenji ^a   Senbonmatsu, Takaaki ^b   Shiotani, Masaharu ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC OBESITY; GLYCEMIC CONTROL; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN SENSITIVITY; KK-AY MOUSE; MALE; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; WEIGHT CONTROL; ZUCKER DIABETIC FATTY RAT; ADIPOSE TISSUE; ANIMAL; BODY WEIGHT; CELL CULTURE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HYPERINSULINISM; OBESITY; ZUCKER RAT;

ANIMALIA; MUS; RATTUS; RODENTIA;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CANAGLIFLOZIN; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DRUG THERAPY, COMBINATION; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; MICE; OBESITY; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES;

EID: 84921904387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116851     Document Type: Article

References (37)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, et al. (2006) Prevalence of overweight and obesity in the United States, 1999-2004. Jama 295: 1549-1555. PMID: 16595758
2. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, et al. (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet 378: 804-814. doi: 10.1016/S0140-6736(11)60813-1 PMID: 21872749
3. Withrow D, Alter DA (2011) The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 12: 131-141. PMID: 20122135
4. Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Lynch JW, et al. (1998) Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care 21: 1637-1643. PMID: 9773723
5. Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106: 473-481.
6. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846. PMID: 17167471
7. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
8. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE (2011) Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 60: 1-23. PMID: 21134520
9. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, et al. (2013) Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 368: 1613-1624. PMID: 23863067
10. Bergenstal RM, Bailey CJ, Kendall DM (2010) Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med 123: 374 e 379-318. doi: 10.1016/j.amjmed.2009.07.017 PMID: 20362759
11. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108: 2941-2948. PMID: 14662691
12. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, et al. (2012) Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14: 539-545. doi: 10.1111/j.1463-1326.2012.01558.x PMID: 22226086
13. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, et al. (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35: 1232-1238. doi: 10.2337/dc11-1926 PMID: 22492586
14. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, et al. (2001) Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132: 578-586. PMID: 11159708
15. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, et al. (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7: e30555. doi: 10.1371/journal.pone.0030555 PMID: 22355316
16. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, et al. (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13: 669-672. doi: 10.1111/j.1463-1326.2011.01406.x PMID: 21457428
17. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-1379.
18. Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, et al. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 16: 467-477. doi: 10.1111/dom.12273 PMID: 24528605
19. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470. PMID: 10480510
20. Finkelstein A, Kunis G, Seksenyan A, Ronen A, Berkutzki T, et al. (2011) Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS. PLoS One 6: e22374. doi: 10.1371/journal.pone.0022374 PMID: 21829620
21. Jia L, Xing J, Ding Y, Shen Y, Shi X, et al. (2013) Hyperuricemia causes pancreatic beta-cell death and dysfunction through NF-kappaB signaling pathway. PLoS One 8: e78284. doi: 10.1371/journal.pone.0078284 PMID: 24205181
22. Muniyappa R, Lee S, Chen H, Quon MJ (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294: E15-26. PMID: 17957034
23. Etgen GJ, Oldham BA (2000) Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 49: 684-688. PMID: 10831184
24. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, et al. (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326: 22-29. PMID: 1727062
25. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104: 787-794. PMID: 10491414
26. Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116: 1802-1812.
27. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110. PMID: 12502499
28. Del Prato S (2009) Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 26: 1185-1192. doi: 10.1111/j.1464-5491. 2009.02847.x PMID: 20002468
29. Nawano M, Oku A, Ueta K, Umebayashi I, Ishirahara T, et al. (2000) Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am J Physiol Endocrinol Metab 278: E535-543. PMID: 10710509
30. Fujimoto Y, Torres TP, Donahue EP, Shiota M (2006) Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats. Diabetes 55: 2479-2490. PMID: 16936196
31. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA (1987) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510-1515. PMID: 3571496
32. Blondel O, Bailbe D, Portha B (1990) Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism 39: 787-793. PMID: 2198430
33. DeFronzo RA, Abdul-Ghani M (2011) Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 34 Suppl 2: S202-209. PMID: 21525456
34. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, et al. (2012) Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20: 1645-1652. doi: 10.1038/oby.2012.59 PMID: 22402735
35. Kuriyama C, Xu JZ, Lee SP, Qi J, Kimata H, et al. (2014) Analysis of the Effect of Canagliflozin on Renal Glucose Reabsorption and Progression of Hyperglycemia in Zucker Diabetic Fatty Rats. J Pharmacol Exp Ther.
36. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, et al. (2008) Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327: 268-276. doi: 10.1124/jpet.108.140210 PMID: 18583547
37. Kurosaki E, Ogasawara H (2013) Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 139: 51-59. doi: 10.1016/j.pharmthera.2013.04.003 PMID: 23563279